Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Overview and Financial Outlook

Goldman Sachs analyst Andrea Tan sets a price target of $571 for NASDAQ:MDGL, indicating a potential upside of 15.61%.Madrigal Pharmaceuticals participates in the 44th Annual J.P. Morgan Healthcare Conference, potentially influencing its stock performance.The company's stock has experienced significant fluctuations over the past year, with a high of$ 615 and a low of $265.Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies for cardiovascular ...